Found: 12
Select item for more details and to access through your institution.
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 5, p. 715, doi. 10.1111/ejh.14065
- By:
- Publication type:
- Article
P-184: Regional differences in treatment and outcome for myeloma patients in Sweden: a population based Swedish Myeloma Register study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S138, doi. 10.1016/S2152-2650(21)02311-9
- By:
- Publication type:
- Article
Over 10 years relative median survival in MM patients ≤ 65 years with VGPR or better on 1st line treatment. Population-based data on patients diagnosed 2008-2018 from the Swedish Myeloma Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e209, doi. 10.1016/j.clml.2019.09.347
- By:
- Publication type:
- Article
Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e85, doi. 10.1016/j.clml.2017.03.153
- By:
- Publication type:
- Article
European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e62, doi. 10.1016/j.clml.2017.03.113
- By:
- Publication type:
- Article
Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.
- Published in:
- Cancer Reports, 2022, v. 5, n. 11, p. 1, doi. 10.1002/cnr2.1614
- By:
- Publication type:
- Article
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 6, p. 2256, doi. 10.1002/cam4.1422
- By:
- Publication type:
- Article
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 5, p. 684, doi. 10.1111/bjh.12685
- By:
- Publication type:
- Article
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13045-020-00948-5
- By:
- Publication type:
- Article
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.
- Published in:
- Cancers, 2024, v. 16, n. 5, p. 1024, doi. 10.3390/cancers16051024
- By:
- Publication type:
- Article
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article